Tirzepatide has emerged as a groundbreaking treatment for type 2 diabetes, offering promising outcomes. However, the cost of this innovative drug and its access have become key concerns for patients and healthcare practitioners. While tirzepatide has been authorized by regulatory agencies, its expensive nature presents a significant obstacle to ma